Aligos TherapeuticsALGS
About: Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Employees: 68
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
7.93% less ownership
Funds ownership: 63.04% [Q2] → 55.11% (-7.93%) [Q3]
11% less capital invested
Capital invested by funds: $16.6M [Q2] → $14.7M (-$1.9M) [Q3]
45% less funds holding
Funds holding: 49 [Q2] → 27 (-22) [Q3]
88% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 25
96% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 23
100% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 0 (-2) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Ed Arce 54% 1-year accuracy 79 / 146 met price target | 88%upside $75 | Buy Reiterated | 7 Nov 2024 |